Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.
about
Docetaxel in the treatment of gastric cancer.Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma.FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.
P2860
Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.
@ast
Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.
@en
type
label
Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.
@ast
Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.
@en
prefLabel
Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.
@ast
Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.
@en
P2093
P356
P1433
P1476
Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer.
@en
P2093
P304
P356
10.1093/ANNONC/MDI281
P577
2005-06-14T00:00:00Z